相关实验视频
Updated: May 29, 2025

10:22
Humanized Mediator Release Assay as a Read-Out for Allergen Potency
Published on: June 29, 2021
3.5K
在患有慢性自发性疹症的患者中,IgE作为奥马利祖马布反应的预测因子
Luis Felipe Ensina1, Larissa Brandão1, Luisa Karla Arruda2
1Department of Pediatrics, Federal University of São Paulo, São Paulo, Brazil.
Frontiers in allergy
|February 7, 2025
概括
基线总免疫球蛋白E (IgE) 水平可以预测慢性自发性疹 (CSU) 中的奥马利祖马布反应. 较低的基线IgE (<59.5 IU/ml) 可能表明反应迟缓,有助于为CSU患者选择治疗.
科学领域:
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性自发性疹 (CSU) 是一种使人虚弱的疾病,通常不耐标准治疗.
- 奥马利祖马布是一种有效的CSU生物疗法,但预测患者的反应仍然是一个挑战.
研究的目的:
- 调查基线总免疫球蛋白E (IgE) 水平是否可以预测慢性自发性疹症患者对奥马利祖马布的治疗反应.
- 为了确定一个潜在的生物标志物,对马利祖马布在耐火性CSU的疗效.
主要方法:
- 来自巴西七个中心的耐火性CSU患者的回顾性分析.
- 在接受奥马利祖马布治疗的患者中评估基线总IgE水平.
- 在omalizumab响应者和不响应者之间IgE水平的比较.
主要成果:
- 奥马利祖马布治疗导致CSU患者的症状显著减少.
- 与响应者相比,对奥马利祖马布无反应者表现出较低的基线总IgE水平.
- 基线IgE水平为59.5 IU/ml显示了67.8%的灵敏度和93.3%的特异性,用于预测奥马利祖马布的反应.
- 较低的IgE基线水平 (<59.5 IU/ml) 可能表明对奥马利祖马布的晚期反应的可能性.
结论:
- 基线总IgE水平作为CSU中奥马利祖马布反应的潜在预测生物标志物.
- 确定基线IgE较低的患者可能有助于预测延迟反应,优化治疗策略.
- 需要进一步的多中心研究与多样化的人口来验证这些发现,并改进预测模型.
相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
231
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
231
Allergic Reactions
27.2K
Overview
27.2K
Allergic Drug Reactions
806
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
806
Cross-reactivity
30.9K
Overview
30.9K

